Mabvax Therapeutics Holdings Inc., of San Diego, completed enrollment and dosing in the initial cohort of a phase I trial testing its antibody-based radioimmunotherapy, MVT-1075, for the treatment of pancreatic, colon and lung cancers. The trial is designed to determine the maximum tolerated dose and safety profile of MVT-1075, but the trial will also measure tumor response rate and duration of response by RECIST 1.1, and determine dosimetry and pharmacokinetics. Interim data are expected in the first quarter of 2018.